Executive Director of Global Value Access and Policy, Amgen
Chad Pettit has worked with biotechnology company Amgen for nearly 20 years, He currently serves as a liaison with biopharmaceutical companies on biosimilar policy, and is working to ensure commercialization leads to cost savings.
Price: one the of largest barriers to medical treatment and accessible medicine. As many patients struggle to afford the high price tags at the pharmacy, there might soon be a solution. As more biosimilars enter the commercia...